LARIX BIOSCIENCE LLC

Sunnyvale, CA · Biotech · Private

Stable chimeric albumin- or IgG Fc-fused hormone biologics and hormone-based nanomedicines for enhanced tissue regeneration

Grants
$12M
39 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
4
2 granted · 2 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Human Glyco-engineered CHO Cells$196,091
Federal grantDepartment of Health and Human Services · Phase I · Human Glyco-engineered CHO Cells$196,091
Federal grantDepartment of Health and Human Services · Phase I · Novel targeted therapeutic for advanced metastatic disease$224,981
Federal grantDepartment of Health and Human Services · Phase I · Novel targeted therapeutic for advanced metastatic disease$224,981
Federal grantDepartment of Health and Human Services · Phase I · Novel monobody therapy for pancreatic cancer$224,981
Federal grantDepartment of Health and Human Services · Phase II · Human glyco-engineered CHO cells$700,809
Federal grantDepartment of Health and Human Services · Phase II · Human glyco-engineered CHO cells$1,489,394
Federal grantDepartment of Health and Human Services · Phase I · Novel therapy for Goodpasture syndrome$224,393
Federal grantDepartment of Health and Human Services · Phase I · Novel therapy for Goodpasture syndrome$224,393
Federal grantDepartment of Health and Human Services · Phase I · Novel therapy for atopic dermatitis$224,981
Federal grantDepartment of Health and Human Services · Phase II · Human glyco-engineered CHO cells$788,585
Federal grantDepartment of Health and Human Services · Phase I · Targeting innate immunity in Type 1 diabetes$224,981
Federal grant· 1 of 2 same dayDepartment of Health and Human Services · Phase I · Novel GPCR-targeted therapy for preeclampsia$224,986
Federal grant· 2 of 2 same dayDepartment of Health and Human Services · Phase I · Novel GPCR-targeted therapy for preeclampsia$224,986
Federal grantDepartment of Health and Human Services · Phase I · Dual Intracellular and Extracellular Expression Technology (dIEE) for Alzheimer’s Disease$224,981
Federal grantDepartment of Health and Human Services · Phase I · Dual Intracellular and Extracellular Expression Technology (dIEE) for Parkinson’s Disease$225,000
Federal grant· 1 of 2 same dayDepartment of Health and Human Services · Phase I · Targeting TGF-beta activation in tumors$224,981
Federal grant· 2 of 2 same dayDepartment of Health and Human Services · Phase I · Targeting TGF-beta activation in tumors$224,981
Federal grantDepartment of Health and Human Services · Phase I · Novel anti-fibrotic therapy for IPF$224,924
Federal grantDepartment of Health and Human Services · Phase I · Targeted therapeutic for Netherton syndrome$252,000
Federal grantDepartment of Health and Human Services · Phase I · Targeted Therapy for Type 1 diabetes$250,000
Federal grantDepartment of Health and Human Services · Phase I · Inhibiting GPR146 in hypercholesterolemia$249,734
Federal grantDepartment of Health and Human Services · Phase I · Novel therapy for myocardial ischemia-reperfusion injury$252,000
Federal grantDepartment of Health and Human Services · Phase I · Novel therapy for myocardial ischemia-reperfusion injury$252,000
Federal grantDepartment of Health and Human Services · Phase I · Therapeutic antibody for cancer-associated cachexia$252,282
Federal grantDepartment of Health and Human Services · Phase I · Therapeutic antibody for anorexia nervosa$259,606
Federal grantDepartment of Health and Human Services · Phase I · Pan-COVID Therapeutic$275,766
Federal grantDepartment of Health and Human Services · Phase I · Advancing a novel therapy for preeclampsia$385,000
Federal grantDepartment of Health and Human Services · Phase I · PA21-259, PHS 2021-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical$275,766
Federal grantDepartment of Health and Human Services · Phase I · Therapeutic antibody for hyperemesis gravidarum$300,847
Federal grantDepartment of Health and Human Services · Phase I · Improved carnosic acid congener compounds for Alzheimer’s disease$326,205
Federal grantDepartment of Health and Human Services · Phase I · Pan-COVID Therapeutic Abstract Severe COVID-19$275,766
Federal grantDepartment of Health and Human Services · Phase I · Silencing autoantibody secretion for SLE therapy$299,865
Federal grantDepartment of Health and Human Services · Phase I · Novel therapies for obesity- or diabetes-related lymphatic dysfunction$245,728
Federal grantDepartment of Health and Human Services · Phase I · Novel therapies for obesity- or diabetes-related lymphatic dysfunction$245,728
Federal grantDepartment of Health and Human Services · Phase I · Overcoming pressure ulcers with engineered hormones and stem cells$295,923
Federal grantDepartment of Health and Human Services · Phase I · Overcoming pressure ulcers with engineered hormones and stem cells$295,923
Federal grantDepartment of Health and Human Services · Phase I · Therapy for ectopic calcification in pseudoxanthoma elasticum$285,766
Federal grantDepartment of Health and Human Services · Phase I · Silencing autoantibody secretion for SLE therapy$299,773
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1164YOURCHOICE THERAPEUTICS INC——
1165ABALONE BIO, INC.——
1166Arcus Biosciences——
1167LARIX BIOSCIENCE LLC——
1168Neumentum, Inc.—$27M
1169Tioga Pharmaceuticals Inc—$24M
1170KODIAK BP, LLC—$13M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 2 granted of 4

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.